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Progressive Supranuclear Palsy–Like
Phenotype in a GBA E326K Mutation Carrier
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Mutations in the beta-glucocerebrosidase gene (GBA OMIM
*606463), encoding the lysosomal enzyme that is deficient in
Gaucher’s disease (GD), are important and common risk factors
for Parkinson’s disease (PD) and Lewy body dementia (LBD; i.e.,
a-synucleinopathies).1 PD patients with GBA mutations have
younger age at onset and are more likely to develop cognitive
dysfunction.2 There are approximately 300 known GBA muta-
tions and determining accurate exact genotype-phenotype corre-
lations is challenging. In general, GBA mutations were found to
variably influence PD risk according to their impact on the pro-
tein function. For instance, the “severe” mutations L444P bears
the highest risk of developing PD (OR:10–21), whereas the risk
is much lower for the “mild” mutation N370S.3 The GBA vari-
ant, E326K, has long been considered a polymorphism, given
that homozygous individuals do not develop GD.4 However, this
variant was found to reduce GBA enzymatic activity in vitro and
mildly increase the risk to develop PD (OR:1.7), with frequent
development of associated dementia.3,5
The impact of GBA mutations on the risk to develop tauopa-
thies is less defined, given that previous studies failed to report a
significant association with PSP and corticobasal degeneration.6
Yet, more recent data suggest that the clinical phenotype of
GBA-associated neurodegeneration is more heterogeneous
than previously assumed, including phenotypes distinct from
a-synucleinopathies.7
Herein, we report on a patient with an unusual phenotype char-
acterized by supranuclear vertical gaze palsy at onset with late emer-
gence of postural instability carrier of the GBA E326K variant.
Case Report
A 51-year-old man was referred to our clinic for a subjective
feeling of dizziness and depression for the past 3 years. He
specifically complained of difficulties in driving and going down
the stairs, but he denied any falls. Familial history was negative
for neurological disorders. On examination, he presented with
supranuclear vertical gaze palsy and staring gaze as well as slow
and hypometric horizontal saccades with increased latency. Nei-
ther overt parkinsonism nor cerebellar signs nor postural insta-
bility were detected (see Video 1, Segment 1). When PD
nonmotor symptoms were investigated, he reported depression
and mild apathy, but denied any hallucinations. He did not
report constipation nor hyposmia nor vivid dreams/acting out
during sleeping (both suggestive of rapid eye movement sleep
behavior disorder [RBD]). At that time, a descriptive clinical
diagnosis of supranuclear vertical gaze palsy was made. A trial
with rasagiline and levodopa (800 mg/day) was attempted with
no response. Brain MRI was unremarkable (Fig. 1A). Neu-
ropsychological examination showed a Mini–Mental State
Examination (MMSE) score of 29/30 with mild impairment in
immediate and delayed recall verbal memory, whereas frontal,
visuospatial, and constructive functions were within the normal
range, although in the lower side. Cognitive evaluation was
repeated 1 year later, showing an MMSE score of 27/30 along
with overt executive and visuospatial deficit and severe apathy.
Last assessment was performed at the age of 54 years, after
6 years from onset (see Video 1, Segment 2). He complained of
dysphagia and frequent falls. At this stage, the patient presented
a PSP-like phenotype. Brain MRI was repeated and showed
mild frontal lobe and midbrain atrophy (Fig. 1B).
Because he reported a long-standing history of nonalcoholic,
nonviral liver enlargement and steatosis, although without sple-
nomegaly, adult forms of Niemann-Pick type C disease (NPC)
or GD were suspected in the first place. Because Filipin staining
of skin biopsy showed inconclusive results as regards the diag-
nosis of NPC, conventional sequencing of coding regions and
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exon-intron boundaries of both NPC1 and NPC2 genes was
performed, failing to identify pathogenic mutations. Subsequent
sequencing of the whole coding sequence of the GBA gene dis-
closed only the E326K variant in a heterozygous state. A single-
photon emission computed tomography (SPECT) DaTscan
showed severe bilateral uptake reduction in both putamen and
caudate (Fig. 1C), whereas 18F-fluorodeoxyglucose ([18F]
FDG)-PET (Fig. 1D,E) revealed a pattern of metabolic alter-
ations similar to that reported in PSP patients.8
All known genes associated to PSP-like phenotypes or atypi-
cal parkinsonism with supranuclear gaze palsy were investigated.
Pathogenic GGGGCC repeat expansions in the C9orf72 gene
(>60 repetitions) were excluded by fluorescent fragment-length
polymerase chain reaction analysis. Haloplex-based targeted
sequencing (on a MiSeq Illumina platform; Illumina, San Diego,
CA) was adopted to simultaneously investigate mutations in the
LRRK2, ATP13A2, FBXO7, MAPT, POLG1, and C10orf2
genes, as well as in several other genes causative of other
parkinsonian syndromes (C19orf12, COASY, DJ-1, DNAJC6,
EIF4G1FA2H, PANK2, PARK2, PINK1, PLA2G6, SNCA,
SYNJ1, VPS35, and WDR45). Moreover, quantitative copy
number analysis by Multiplex Ligation–dependent Probe
Amplification (SALSA MLPA Kit P051 Parkinson; MRC-
Holland BV, Amsterdam, the Netherlands) was used to search
for exon deletions or multiplications in PD-related genes. All
these studies yielded negative results.
Besides its mild effect on the risk to develop PD, the E326K
variant was also detected in patients with other a-synucleinopa-
thies such as PD dementia, LBD, and MSA, and, more rarely,
in patients with other movement disorders, such as essential tre-
mor and Machado Joseph disease with parkinsonian phenotype
and mutation in spinocerebellar ataxia type 3.9,10 However, this
variant was found with similar frequency in healthy control
groups, questioning its effective contribution in determining
these phenotypes.
To date, GBA mutations have been reported only in 3 of
257 PSP patients, but none of them carried the E326K variant.
However, because GBA screening was limited to searching the
Figure 1 First brain MRI showing unremarkable findings (A) and second brain MRI after 2.5 years showing mild midbrain atrophy (B).
I-123 FP-CIT SPECT DaTscan (C) showing severe nigrostriatal deficit. Axial (D) and sagittal (E) 18FDG-PET images showing relative
hypometabolism in the frontal cortex, anterior cingulate, and, to a lesser extent, in the striatum.
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two common mutations, N370S and L444P, in one study, and to
sequencing exons 9 and 10 in the other one, the occurrence of
other GBA mutations, including E326K, in PSP patients cannot
be ruled out at present.6,7 Although the clinical features, the lack
of typical PD nonmotor symptoms (i.e., constipation, hyposmia,
and RBD), and the absence of response to L-dopa, prompted us
to speculate a tauopathy as the underlying pathology, we cannot
exclude that our patient might have a synucleinopathy alone or in
addition to tauopathy.11
The E326K has been reported as a polymorphic variant, with
a global frequency in the European population of around 1%
according to public databases (e.g., ExAC, EVS). In line with
these figures, we detected 1 E326K carrier among a cohort of
103 Italian healthy controls. Because of these observations,
along with the lack of data on the frequency of E326K in PSP
patients, we cannot confidently exclude that our finding is an
incidental discovery. On the other hand, the early impairment
in horizontal eye movements might support the pathogenic role
of the E326K variant, given that increased latency of horizontal
saccades has been described in type 3 GD.12
Further comprehensive screenings of the GBA gene in larger
cohorts of PSP-like patients are needed to better assess the poten-
tial impact of this gene in determining PSP-like phenotype.
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Supporting Information
A video accompanying this article is available in the supporting
information here.
Video 1. Segment 1: Gait characterized by hesitation during
turning with normal tandem. Mild reduced arm swing. Pull test
negative. Slight dysarthria. Staring gaze with frontalis muscle
overactivity. Impaired finger tapping (left > right). Slowing of
the saccades and limitation of the vertical gaze during both sac-
cades and smooth pursuit of a target. The gaze limitation can
be overcome by eliciting the vestibulo-ocular reflex. Extreme
slowing of saccades resembling smooth pursuit may be observed
on the horizontal plane as well. Segment 2: Severe gait impair-
ment with need of assistance. Pull test positive. Severe dysar-
thria and marked staring gaze. Impaired finger tapping
(left > right). Severe limitation of the eye movements with
absence of saccades and extreme slowness of smooth pursuit,
which are present only on the horizontal plane. Still, the gaze
limitation can be overcome by the vestibulo-ocular reflex.
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